title: Radiosensitization of Glioblastoma Cell Lines by the Dual PI3K and mTOR Inhibitor NVP-BEZ235 Depends on Drug-Irradiation Schedule.
abstract: Previous studies have shown that the dual phosphatidylinositide 3-kinase/mammalian target of rapamycin (PI3K/mTOR) inhibitor NVP-BEZ235 radiosensitizes tumor cells if added shortly before ionizing radiation (IR) and kept in culture medium thereafter. The present study explores the impact of inhibitor and IR schedule on the radiosensitizing ability of NVP-BEZ235 in four human glioblastoma cell lines. Two different drug-IR treatment schedules were compared. In schedule I, cells were treated with NVP-BEZ235 for 24 hours before IR and the drug was removed before IR. In schedule II, the cells were exposed to NVP-BEZ235 1 hour before, during, and up to 48 hours after IR. The cellular response was analyzed by colony counts, expression of marker proteins of the PI3K/AKT/mTOR pathway, cell cycle, and DNA damage. We found that under schedule I, NVP-BEZ235 did not radiosensitize cells, which were mostly arrested in G1 phase during IR exposure. In addition, the drug-pretreated and irradiated cells exhibited less DNA damage but increased expressions of phospho-AKT and phospho-mTOR, compared to controls. In contrast, NVP-BEZ235 strongly enhanced the radiosensitivity of cells treated according to schedule II. Possible reasons of radiosensitization by NVP-BEZ235 under schedule II might be the protracted DNA repair, prolonged G2/M arrest, and, to some extent, apoptosis. In addition, the PI3K pathway was downregulated by the NVP-BEZ235 at the time of irradiation under schedule II, as contrasted with its activation in schedule I. We found that, depending on the drug-IR schedule, the NVP-BEZ235 can act either as a strong radiosensitizer or as a cytostatic agent in glioblastoma cells.
authors.affiliation: Department of Radiation Oncology, University of Würzburg, Würzburg, Germany.
authors.forename: Sebastian
authors.initials: S
authors.lastname: Kuger
authors.forename: Dorothea
authors.initials: D
authors.lastname: Graus
authors.forename: Rico
authors.initials: R
authors.lastname: Brendtke
authors.forename: Nadine
authors.initials: N
authors.lastname: Günther
authors.forename: Astrid
authors.initials: A
authors.lastname: Katzer
authors.forename: Paul
authors.initials: P
authors.lastname: Lutyj
authors.forename: Bülent
authors.initials: B
authors.lastname: Polat
authors.forename: Manik
authors.initials: M
authors.lastname: Chatterjee
authors.forename: Vladimir L
authors.initials: VL
authors.lastname: Sukhorukov
authors.forename: Michael
authors.initials: M
authors.lastname: Flentje
authors.forename: Cholpon S
authors.initials: CS
authors.lastname: Djuzenova
references.citation: Mol Cell Biol. 2004 Jan;24(1):200-16
references.pmid: 14673156
references.citation: Mol Cancer Res. 2009 Apr;7(4):601-13
references.pmid: 19372588
references.citation: Oncotarget. 2010 Nov;1(7):530-43
references.pmid: 21317449
references.citation: Nat Protoc. 2008;3(7):1187-93
references.pmid: 18600224
references.citation: PLoS One. 2012;7(1):e29925
references.pmid: 22299028
references.citation: J Biol Chem. 2007 Jul 20;282(29):21206-12
references.pmid: 17513297
references.citation: Curr Top Microbiol Immunol. 2010;347:279-96
references.pmid: 20535652
references.citation: Mol Cancer Ther. 2009 Aug;8(8):2204-10
references.pmid: 19671762
references.citation: Genes Cancer. 2010 Nov;1(11):1124-31
references.pmid: 21779436
references.citation: Cell Signal. 2002 May;14(5):381-95
references.pmid: 11882383
references.citation: J Cancer Res Clin Oncol. 2001 Feb;127(2):91-5
references.pmid: 11216919
references.citation: Cancer Res. 2000 Sep 15;60(18):5303-9
references.pmid: 11016662
references.citation: Cytometry. 1994 Jan 1;15(1):35-45
references.pmid: 8162823
references.citation: Oncogene. 2003 Oct 20;22(47):7486-95
references.pmid: 14576853
references.citation: J Biol Chem. 1998 Mar 6;273(10):5858-68
references.pmid: 9488723
references.citation: Int J Radiat Oncol Biol Phys. 2003 Jul 1;56(3):846-53
references.pmid: 12788194
references.citation: J Cell Biol. 2004 Nov 8;167(3):399-403
references.pmid: 15533996
references.citation: Radiat Oncol. 2009 Oct 14;4:43
references.pmid: 19828040
references.citation: Int J Radiat Oncol Biol Phys. 2005 Nov 15;63(4):1221-7
references.pmid: 16253776
references.citation: Nat Rev Cancer. 2006 Nov;6(11):876-85
references.pmid: 17036041
references.citation: Mol Cell Biol. 2010 Feb;30(4):908-21
references.pmid: 19995915
references.citation: Endocr Relat Cancer. 2001 Sep;8(3):237-48
references.pmid: 11566615
references.citation: Neoplasia. 2012 Jan;14(1):34-43
references.pmid: 22355272
references.citation: Radiat Oncol. 2010 Nov 16;5:108
references.pmid: 21080918
references.citation: Int J Oncol. 2009 Oct;35(4):731-40
references.pmid: 19724909
references.citation: Cancer Biother Radiopharm. 2010 Jun;25(3):317-23
references.pmid: 20578837
references.citation: Nat Rev Cancer. 2002 Jul;2(7):489-501
references.pmid: 12094235
references.citation: Br J Cancer. 2004 Jun 14;90(12):2356-63
references.pmid: 15150571
references.citation: Radiat Res. 2011 Feb;175(2):214-24
references.pmid: 21268715
references.citation: Oncogene. 2007 Mar 22;26(13):1932-40
references.pmid: 17001314
references.citation: Cancer Res. 2006 Jan 15;66(2):981-8
references.pmid: 16424033
references.citation: Cancer Sci. 2008 Sep;99(9):1734-40
references.pmid: 18616528
references.citation: PLoS One. 2011;6(6):e20899
references.pmid: 21695126
references.citation: Cancer Discov. 2011 Aug;1(3):248-59
references.pmid: 22140653
references.citation: Clin Cancer Res. 2010 Jan 15;16(2):530-40
references.pmid: 20068094
references.citation: Clin Cancer Res. 2003 Jun;9(6):2316-26
references.pmid: 12796401
references.citation: Nat Rev Cancer. 2004 May;4(5):335-48
references.pmid: 15122205
references.citation: Cancer Res. 2012 Jan 1;72(1):239-48
references.pmid: 22108822
references.citation: Mol Cancer Res. 2011 Dec;9(12):1696-707
references.pmid: 22009179
references.citation: J Neurosurg. 1978 Sep;49(3):333-43
references.pmid: 355604
references.citation: Cancer Res. 2010 Oct 15;70(20):8097-107
references.pmid: 20876803
references.citation: Clin Cancer Res. 2010 Jul 15;16(14):3628-38
references.pmid: 20606035
references.citation: Cancer Res. 2009 Oct 1;69(19):7644-52
references.pmid: 19789349
references.citation: Radiat Oncol. 2012 Mar 27;7:48
references.pmid: 22452803
references.citation: Mol Cancer Ther. 2008 Jul;7(7):1851-63
references.pmid: 18606717
references.citation: Cancer. 1983 Sep 15;52(6):997-1007
references.pmid: 6349785
references.citation: N Engl J Med. 2005 Mar 10;352(10):987-96
references.pmid: 15758009
references.citation: Oncol Rep. 2010 Dec;24(6):1683-9
references.pmid: 21042768